The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks end with modest gain, but down on week overall

Fri, 26th Sep 2014 16:48

UK stocks ended the final session of the week with a modest rise, although on the week the index was significantly lower.The FTSE 100 closed 9.68 points higher at 6,649.39.Markets are concerned about mounting geopolitical tensions, with the government due to take a vote on whether to participate in a war against the "Islamic State" on Friday evening.David Cameron and Ed Miliband took to the stands in the House of Commons on Friday morning in an attempt to persuade parliament to support airstrikes against Islamic State (IS) militants in Iraq.Cameron urged members to support military action in the region, underlining Britain's clear basis for action in international law, strengthened by a direct request for British intervention made by the Iraqi government.The Prime Minister also highlighted the international coalition's need for Britain's unique military and intelligence capabilities in order to fight the Islamist militant group."Is there a threat to the British people? The answer is yes," Cameron told parliament, saying he thought action would need to last "years" to be effective.Members are expected to vote in favour of entering the conflict.Soaring house prices could drive workers away from LondonLondon could be waving goodbye to a number of workers in the future, as the struggle to meet living costs in the British capital continues to rise.London's housing shortage could put the city's future at risk unless swift actions are taken to address one of the capital's chronic problems, research conducted by YouGov shows.Japanese CPI disappointsLooking abroad, Japanese consumer price inflation came in weaker than expected for August. The headline inflation rate slowed to a 3.3% year-on-year pace from 3.4%, with the ex-fresh food measure down to 3.1% from 3.3% (consensus: 3.2%)."Softer Japanese CPI data reinforced fears of more BoJ easing and hurt the JPY," analysts at UnicreditResearch said.Over in the States, gross domestic product (GDP) was revised higher in the second quarter, supported by better retail sales and foreign trade numbers.The US economy grew at a 4.6% annual rate in the three months to end of June, as predicted by analysts.Easyjet shares take off thanks to comments from JefferiesShares in Easyjet flew higher after Jefferies said the airline was situated to benefit from the recent problems with Air France-KLM, which has been forced to cancel numerous flights due to pilot strike action. The broker also predicted the group would have a positive finish to the year.Astrazeneca shares also squeezed higher after the company received positive feedback for Moventig, its new treatment for opioid-induced constipation.British Land shares were lifted by Societe Generale after it lifted its rating from 'hold' to 'buy'.Meanwhile, Sports Direct shares slumped into the red one day after its boss, Mike Ashley, yesterday surprised the market with the news it has completed a "put" option with Goldman Sachs in a complicated move that it said "reflects Sports Direct's growing relationship with Tesco and belief in Tesco's long-term future". The option relates to 23m Tesco shares.Tesco, together with its sector peers Sainsbury and Morrison, all continued to decline amid the growing price war amongst supermarkets.Slower-than-expected growth in its solutions division and challenging market conditions in its currency division have forced security documents designer and producer De La Rue to issue a profit warning, sending shares sharply lower.The FTSE 250 company said it expects operating profit and underlying profit before tax for the year to be £20m lower than originally estimated.Market MoverstechMARK 2,810.43 +0.37%FTSE 100 6,649.39 +0.15%FTSE 250 15,383.69 -0.27%FTSE 100 - RiserseasyJet (EZJ) 1,393.00p +3.19%St James's Place (STJ) 739.00p +2.78%British Land Co (BLND) 706.00p +2.10%Fresnillo (FRES) 761.50p +1.80%Shire Plc (SHP) 5,330.00p +1.72%ARM Holdings (ARM) 919.00p +1.66%Admiral Group (ADM) 1,253.00p +1.62%International Consolidated Airlines Group SA (CDI) (IAG) 370.70p +1.51%Hammerson (HMSO) 571.50p +1.51%Intu Properties (INTU) 330.50p +1.47%FTSE 100 - FallersSainsbury (J) (SBRY) 250.10p -3.06%Sports Direct International (SPD) 620.50p -2.67%Morrison (Wm) Supermarkets (MRW) 171.00p -1.78%Imperial Tobacco Group (IMT) 2,647.00p -1.78%IMI (IMI) 1,244.00p -1.66%Petrofac Ltd. (PFC) 1,010.00p -1.08%CRH (CRH) 1,389.00p -1.00%BG Group (BG.) 1,127.50p -0.97%TUI Travel (TT.) 387.50p -0.95%3i Group (III) 384.60p -0.88%FTSE 250 - RisersSupergroup (SGP) 1,136.00p +4.22%Fidessa Group (FDSA) 2,303.00p +3.00%Betfair Group (BET) 1,172.00p +2.99%Pets at Home Group (PETS) 176.00p +2.92%Evraz (EVR) 127.10p +2.92%Zoopla Property Group (WI) (ZPLA) 234.90p +2.76%SEGRO (SGRO) 365.40p +2.50%Millennium & Copthorne Hotels (MLC) 556.00p +2.39%Balfour Beatty (BBY) 224.90p +2.13%Capital & Counties Properties (CAPC) 332.40p +2.03%FTSE 250 - FallersDe La Rue (DLAR) 504.00p -33.60%Greencore Group (GNC) 240.80p -4.82%Ocado Group (OCDO) 267.40p -3.67%Daejan Holdings (DJAN) 4,878.00p -3.31%Hochschild Mining (HOC) 139.70p -2.92%Vesuvius (VSVS) 452.50p -2.88%Synthomer (SYNT) 215.00p -2.80%Playtech (PTEC) 716.00p -2.78%African Barrick Gold (ABG) 207.50p -2.72%Soco International (SIA) 372.40p -2.69%
More News
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.